Clinical Trials · NCT00451958
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 386
- Start date
- Mar 2007
- Locations
- 69 sites, 12 countries
- Primary endpoint
- Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight